AVAX TECHNOLOGIES INC
10QSB, EX-27.1, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: AVAX TECHNOLOGIES INC, 10QSB, EX-11.1, 2000-11-14
Next: AMF BOWLING WORLDWIDE INC, 10-Q, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM AVAX
TECHNOLOGIES, INC. STATEMENT OF INCOME FOR YEAR AND NINE MONTHS ENDED DECEMBER
31, 1999 AND SEPTERMBER 30, 2000, RESPECTIVELY, AND BALANCE SHEET AS OF DECEMBER
31, 1999 AND SEPTEMBER 30, 2000, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   12-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999             SEP-30-2000
<PERIOD-START>                             JAN-01-1999             JAN-01-2000
<PERIOD-END>                               DEC-31-1999             SEP-30-2000
<CASH>                                       3,426,059               7,203,396
<SECURITIES>                                 8,868,621              24,243,148
<RECEIVABLES>                                        0                  38,408
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                  43,548
<CURRENT-ASSETS>                            12,631,501              31,986,701
<PP&E>                                       2,458,678               3,241,347
<DEPRECIATION>                                 116,862                 614,847
<TOTAL-ASSETS>                              14,973,317              41,357,446
<CURRENT-LIABILITIES>                          401,263               2,038,531
<BONDS>                                              0                 247,752
                                0                       0
                                      1,752                     867
<COMMON>                                        44,311                  66,167
<OTHER-SE>                                  14,023,650              36,428,881
<TOTAL-LIABILITY-AND-EQUITY>                14,973,317              41,357,446
<SALES>                                              0                 248,003
<TOTAL-REVENUES>                                     0                       0
<CGS>                                                0                 123,569
<TOTAL-COSTS>                                8,551,973              11,901,220
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       0
<INCOME-PRETAX>                            (7,867,563)            (10,111,187)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                        (7,867,563)            (10,111,187)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                               (7,867,563)<F1>            (10,111,187)<F1>
<EPS-BASIC>                                      (.74)                   (.68)
<EPS-DILUTED>                                        0                       0
<FN>
<F1>EPS - BASIC
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission